No Data
No Data
No Data
No Data
No Data
三愛健康集團:二零二三年年報
Futu NewsApr 25 07:27 ET · Announcements
A total of 612 million new shares were issued by Sanai Health Group (01889) in exchange for convertible stock notes
According to the Zhitong Finance App, Sanai Health Group (01889) issued an announcement to issue and distribute 349 million new shares on April 23, 2024 in exchange for convertible notes due in 2026 with a principal amount of HK$34.2 million based on an adjusted exchange price of HK$0.098 per share. On April 23, 2024, 263 million new shares were issued and distributed in exchange for convertible notes due 2026 with a principal amount of HK$25.8 million, based on an adjusted conversion price of HK$0.098 per share.
Zhitong FinanceApr 23 18:52 ET
Sanai Health Unit to Offload 59% Stake in Genetic Testing Provider
Sanai Health Industry Group (HKG:1889) unit Sanai International Investment will sell its 59% equity interest in Zentrogene Bioscience Laboratory to Merit Investment Holding for HK$22 million, accordin
MT NewswiresApr 18 05:43 ET
Sanai Health Group (01889) plans to sell 59% of Zentrogene Bioscience Laboratory Limited's shares for HK$22 million
Sanai Health Group (01889) announced that on April 17, 2024, the company is a wholly-owned subsidiary of Sanai International Investment...
Zhitong FinanceApr 17 10:18 ET
Investors Give Sanai Health Industry Group Company Limited (HKG:1889) Shares A 26% Hiding
To the annoyance of some shareholders, Sanai Health Industry Group Company Limited (HKG:1889) shares are down a considerable 26% in the last month, which continues a horrid run for the company. The
Simply Wall StApr 3 19:23 ET
Sanai Health Group (01889) announced annual results. Profit attributable to shareholders was 18.633 million yuan, a year-on-year decrease of 36.23%
According to the Zhitong Finance App, Sanai Health Group (01889) announced its 2023 annual results, with revenue of about 122 million yuan (RMB, same below); a year-on-year decrease of about 30.59%; profit attributable to company owners was 18.633 million yuan, a year-on-year decrease of 36.23%; profit per share was 0.58 points. According to reports, the decline in earnings was mainly due to a decrease in sales of self-produced pharmaceutical products and sales of pharmaceutical products from other non-competitive pharmaceutical companies.
Zhitong FinanceMar 27 18:15 ET
No Data
No Data